Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health submitted a Form 144 disclosing proposed sales of common stock related to equity compensation and restricted stock lapses. The filing lists a Charles Schwab & Co. intermediary entry for 3,832 shares dated 04/01/2026 and two past sales by Terilyn J. Monroe of 10,031 and 8,571 shares on 01/07/2026 and 01/21/2026, respectively.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 1, 2026, multiple tranches of restricted stock units vested and were exercised into a total of 11,461 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations related to the vesting, 6,013 Common Stock shares were retained by Guardant Health at a price of $91.15 per share, as disclosed in the footnotes. After these transactions, Saia directly held 62,351 Common Stock shares. The RSU awards were originally granted between November 2022 and March 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity tied to restricted stock units. On April 1, 2026, she acquired 8,019 shares of common stock upon vesting and related derivative exercises, then had 4,187 shares withheld by the company to cover tax obligations at $91.15 per share. After these transactions, she directly held 24,822 shares of common stock. The filing reflects compensation and tax withholding mechanics rather than open-market buying or selling.
Guardant Health Chief Information Officer Kumud Kalia reported routine equity compensation activity involving restricted stock units. On April 1, 2026, several restricted stock unit awards converted into a total of 10,044 shares of Common Stock, reflecting scheduled vesting from previously granted awards.
To cover related tax obligations, 5,092 Common Stock shares were withheld by Guardant Health at $91.15 per share, as described in the footnotes, and were not sold in the open market. After these transactions, Kalia directly holds 49,249 Common Stock shares, indicating an overall increase in his equity stake despite the tax withholding.
Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity. On April 1, 2026, multiple installments of his restricted stock unit awards vested, resulting in the acquisition of 11,213 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 4,750 shares were withheld by Guardant Health at a price of $91.15 per share, as noted in the footnotes. After these transactions, Freeman directly owned 60,034 shares of Guardant Health common stock. The RSU awards were originally granted between November 7, 2022 and March 12, 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief Medical Officer Craig Eagle reported routine equity compensation activity as several restricted stock unit awards vested on April 1, 2026. He exercised RSUs to acquire a total of 11,400 shares of common stock at an exercise price of $0.00 per share.
To satisfy related tax obligations, 5,779 shares of common stock were retained by the company at $91.15 per share, as described in the footnotes, rather than sold on the open market. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity tied to vesting restricted stock units. On April 1, 2026, she acquired a total of 13,029 shares of Guardant Health common stock through the exercise and conversion of multiple restricted stock unit awards at a stated price of $0.00 per share.
To cover tax withholding obligations upon vesting, 7,005 shares were retained by the company at a price of $91.15 per share, as described in the footnotes. After these compensation-related transactions and tax withholding, Chudova directly holds 70,376 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell exercised restricted stock units into common shares and had shares withheld for taxes. On April 1, 2026, he converted multiple restricted stock unit awards into a total of 12,777 shares of common stock at a conversion price of $0.00 per share.
In a related tax-withholding transaction, 6,869 common shares were retained by the company at $91.15 per share to satisfy tax liabilities tied to the RSU vesting. After these transactions, Bell directly held 49,509 shares of Guardant Health common stock, reflecting routine equity compensation activity rather than an open-market trade.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock on March 31 and April 1, 2026. Several RSU awards vested and were converted into shares of common stock held largely through the Talasaz and Eskandari 2017 Family Trust. In connection with these vestings, a total of 18,515 shares of common stock were withheld by the company at prices of $92.37 and $91.15 per share to satisfy tax withholding obligations, rather than sold in open-market transactions. Following these transactions, the family trust held 2,146,504 shares of Guardant Health common stock, while Talasaz also retained a substantial number of unvested RSUs directly.
Guardant Health, Inc. co-Chief Executive Officer Helmy Eltoukhy reported routine equity compensation activity involving restricted stock units and related common stock. On March 31 and April 1, 2026, multiple restricted stock unit awards converted into an aggregate of tens of thousands of shares of common stock at a $0.00 exercise price.
To cover associated tax obligations upon these vesting events, a total of 18,515 shares of common stock were retained by the company at prices of $92.37 and $91.15 per share, characterized as tax-withholding dispositions rather than open-market sales. Following these transactions, a revocable trust associated with Eltoukhy held 2,112,919 shares of common stock, and he directly held 68,011 restricted stock units. The filing reflects compensation-related vesting and tax withholding, not discretionary market trading.